Personalising osteoporosis treatment for patients at high risk of fracture.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed.

1. Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk: a post hoc analysis of the first year of the frame study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2021
   Trial
2. Rapid and relaying deleterious effects of a gastrointestinal pathogen,iScience · 2025
   Article
3. Early Menopause and Risk of Fractures-A Preventable Gap.Iranian journal of public health · 2023
   Article
4. Study on the influence of balloon dilation mode on the intravertebral cleft of osteoporotic fracture.BMC surgery · 2022
   Article
5. CMTM3 suppresses bone formation and osteogenic differentiation of mesenchymal stem cells through inhibiting Erk1/2 and RUNX2 pathways.Genes & diseases · 2021
   Article
6. Investigation of Diagnostic Biomarkers for Osteoporosis Based on Differentially Expressed Gene Profile with QCT and mDixon-Quant Techniques.Orthopaedic surgery · 2021
   Article
7. Bone mineral density response prediction following osteoporosis treatment using machine learning to aid personalized therapy.Scientific reports · 2021
   Article
8. A service evaluation of e-triage in the osteoporosis outpatient clinic-an effective tool to improve patient access?Archives of osteoporosis · 2020
   Article

Corrections and comments

• Comment on
  Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial.2019

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as